Chemotherapy and peripheral neuropathy

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Neurological Sciences

• Publication date

  2021-08-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10072-021-05576-6PMID 34436727
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis

  2021cited by this paper
• Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

  2021cited by this paper
• Risk Factors for Chemotherapy-Induced Peripheral Neuropathy

  2021cited by this paper
• Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy

  2021cited by this paper
• Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response.

  2021cited by this paper
• Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in Sarm1-/- mice.

  2021cited by this paper
• Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review

  2021cited by this paper
• Cancer Statistics, 2021

  2021cited by this paper
• Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes.

  2021cited by this paper
• Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study

  2021cited by this paper
• SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration.

  2021cited by this paper
• Prevalence, correlates, and impact of sleep disturbance in Chinese meningioma patients

  2021cited by this paper
• The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors

  2021cited by this paper
• Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy

  2021cited by this paper
• Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update.

  2020influential reference
• Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial

  2020cited by this paper
• Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial

  2020cited by this paper
• Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin

  2020cited by this paper
• Peripheral neuropathy in hematologic malignancies - Past, present and future.

  2020cited by this paper
• Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.

  2020cited by this paper
• Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724)

  2020cited by this paper
• Genome-Wide Meta-Analysis Validates a Roless for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.

  2020influential reference
• Role for Drug Transporters in Chemotherapy‐Induced Peripheral Neuropathy

  2020cited by this paper
• Vincristine- and bortezomib-induced neuropathies - from bedside to bench and back.

  2020cited by this paper
• Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up†.

  2020cited by this paper
• Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study

  2020cited by this paper
• Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms

  2020cited by this paper
• Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy

  2019cited by this paper
• Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

  2019cited by this paper
• Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy.

  2019cited by this paper
• Platinum‐induced peripheral neurotoxicity: From pathogenesis to treatment

  2019influential reference
• Taxane and epothilone‐induced peripheral neurotoxicity: From pathogenesis to treatment

  2019cited by this paper
• Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment

  2019cited by this paper
• Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer

  2019cited by this paper
• Paclitaxel-induced peripheral neuropathy is caused by epidermal ROS and mitochondrial damage through conserved MMP-13 activation

  2019cited by this paper
• Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview

  2019cited by this paper
• Quantification of Small Fiber Neuropathy in Chemotherapy Treated Patients.

  2019cited by this paper
• Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis.

  2019cited by this paper
• Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy

  2019cited by this paper
• Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy

  2019cited by this paper
• Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials

  2019cited by this paper
• Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.

  2019cited by this paper
• Sphingosine-1-phosphate signaling: A novel target for simultaneous adjuvant treatment of triple negative breast cancer and chemotherapy-induced neuropathic pain.

  2019cited by this paper
• Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)

  2018cited by this paper
• Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes

  2018cited by this paper
• Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

  2018cited by this paper
• Risk factors for the development of paclitaxel‐induced neuropathy in breast cancer patients

  2018cited by this paper
• Pharmacogenomics of Vincristine‐Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes

  2018cited by this paper
• Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy

  2018cited by this paper
• Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

  2018cited by this paper
• Age and the Risk of Paclitaxel‐Induced Neuropathy in Women with Early‐Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101

  2018cited by this paper
• Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity

  2018cited by this paper
• Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.

  2018cited by this paper
• A Mechanistic Understanding of Axon Degeneration in Chemotherapy-Induced Peripheral Neuropathy

  2017cited by this paper
• Depletion of Mitofusin-2 Causes Mitochondrial Damage in Cisplatin-Induced Neuropathy

  2017cited by this paper
• Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study

  2017cited by this paper
• The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.

  2017cited by this paper
• Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome

  2017cited by this paper
• Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy

  2017cited by this paper
• Short‐term recovery of chemotherapy‐induced peripheral neuropathy after treatment for pediatric non‐CNS cancer

  2017cited by this paper
• Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis
.

  2017cited by this paper
• Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics

  2017cited by this paper
• Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability

  2017cited by this paper
• Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy.

  2017cited by this paper
• Vincristine‐induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia

  2017cited by this paper
• Paclitaxel-induced painful neuropathy is associated with changes in mitochondrial bioenergetics, glycolysis, and an energy deficit in dorsal root ganglia neurons

  2017cited by this paper
• Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

  2017cited by this paper
• Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

  2016cited by this paper
• Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT).

  2016cited by this paper
• Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

  2016cited by this paper
• Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy

  2016cited by this paper
• Lenalidomide long-term neurotoxicity

  2016cited by this paper
• Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.

  2016cited by this paper
• Serum micronutrients and prealbumin during development and recovery of chemotherapy‐induced peripheral neuropathy

  2016cited by this paper
• Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.

  2016influential reference
• A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma

  2016cited by this paper
• Chemotherapy-Induced Neurotoxicity: Evidence of a Protective Role of CC Homozygosis in the Interleukin-1β Gene-511 C>T Polymorphism

  2016cited by this paper
• Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy

  2016cited by this paper
• Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy.

  2016cited by this paper
• Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)

  2016cited by this paper
• Paclitaxel inhibits mRNA transport in axons.

  2015cited by this paper
• Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).

  2015cited by this paper
• Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN)

  2015cited by this paper
• Brentuximab vedotin: axonal microtubule's Apollyon

  2015cited by this paper
• Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2015cited by this paper
• Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial

  2015cited by this paper
• Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.

  2015influential reference
• Patterns and severity of vincristine‐induced peripheral neuropathy in children with acute lymphoblastic leukemia

  2015cited by this paper
• Taxane-Induced Peripheral Neurotoxicity

  2015cited by this paper
• Toxic Effects of Bortezomib on Primary Sensory Neurons and Schwann Cells of Adult Mice

  2015cited by this paper
• Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel—Letter

  2015influential reference
• Long‐term course of oxaliplatin‐induced polyneuropathy: a prospective 2‐year follow‐up study

  2014cited by this paper
• Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel

  2014cited by this paper
• Bortezomib‐ and thalidomide‐induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study

  2014cited by this paper
• A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration

  2014cited by this paper
• XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis

  2014cited by this paper
• Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

  2013cited by this paper
• Advanced age and liability to oxaliplatin‐induced peripheral neuropathy: post hoc analysis of a prospective study

  2013cited by this paper
• Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy.

  2013cited by this paper
• Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy

  2013influential reference

• Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

  2025cites this paper
• Determination of the Effect of Neuropathic Pain on Quality of Life in Cancer Patients Receiving Chemotherapy

  2025cites this paper
• Dimethoxybenzohomoadamantane-based soluble epoxide hydrolase inhibitors: in vivo efficacy in a murine model of chemotherapy-induced neuropathic pain

  2025cites this paper
• Feet Cooling As a Preventive Strategy against Chemotherapy-Induced Peripheral Neuropathy in Advanced Breast Cancer Patients: A Randomized Clinical Trial.

  2025cites this paper
• Histological Study on the Effect of Taurine on Cisplatin Induced Sciatic Nerve Neuropathy in Adult Male Albino Rats.

  2025cites this paper
• The Incidence of acute Neurotoxicity among some Iraqi colorectal cancer patients treated with oxaliplatin-based chemotherapy

  2025cites this paper
• Percutaneous Peripheral Nerve Stimulation in Chemotherapy-Induced Neuropathy: A Case Report

  2025cites this paper
• Enhancing Duloxetine With Mirogabalin for Treating Taxane-Induced Peripheral Neuropathy in Advanced Lung Cancer

  2025cites this paper
• Distinct Trajectories of Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Survivors Treated With R-CHOP.

  2025cites this paper
• Chemotherapy-related trigeminal and glossopharyngeal nerves neurotoxicity: a cohort study.

  2024cites this paper
• Impact d’un programme de rééducation multimodale démarré précocement sur l’apparition de douleurs neuropathiques induites par la chimiothérapie chez les patientes atteintes d’un cancer du sein

  2024cites this paper
• A study concept of expeditious clinical enrollment for genetic modifier studies in Charcot–Marie–Tooth neuropathy 1A

  2024cites this paper
• Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes

  2024cites this paper
• Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy

  2024cites this paper
• Chemical compounds, anti-tumor and anti-neuropathic pain effect of hemp essential oil in vivo.

  2024cites this paper
• Chemotherapy-Induced Peripheral Neuropathy: Assessment and Treatment Strategies for Advanced Practice Providers.

  2024cites this paper
• Cannabis sativa L. Extract Alleviates Neuropathic Pain and Modulates CB1 and CB2 Receptor Expression in Rat

  2024cites this paper
• A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine

  2024cites this paper
• Modulation of chemotherapy-induced peripheral neuropathy by JZL195 through glia and the endocannabinoid system.

  2024cites this paper
• A Comparative Study of Tumor-Specificity and Neurotoxicity between 3-Styrylchromones and Anti-Cancer Drugs

  2023cites this paper
• Chemotherapy-Induced Peripheral Neuropathy: Diagnosis, Agents, General Clinical Presentation, and Treatments

  2023cites this paper
• Circulating microRNAs can predict chemotherapy-induced toxicities in patients being treated for primary breast cancer

  2023cites this paper
• Gut microbiota in chronic pain: Novel insights into mechanisms and promising therapeutic strategies.

  2023cites this paper
• Randomized clinical trial quantifying the effectiveness of a self-monitoring intervention in cancer patients with peripheral neuropathy: A quantitative study

  2023cites this paper
• Understanding Characteristics, Treatment Patterns, and Clinical Outcomes for Individuals with Advanced or Recurrent Endometrial Cancer in Alberta, Canada: A Retrospective, Population-Based Cohort Study

  2023cites this paper
• Evaluation of neurotoxicity of anticancer drugs using nematode Caenorhabditis elegans as a model organism.

  2023cites this paper
• Gabapentin Increases Intra-Epidermal and Peptidergic Nerve Fibers Density and Alleviates Allodynia and Thermal Hyperalgesia in a Mouse Model of Acute Taxol-Induced Peripheral Neuropathy

  2022cites this paper
• Towards a mechanistic understanding of axon transport and endocytic changes underlying paclitaxel-induced peripheral neuropathy.

  2022cites this paper
• Effects of vitamin E in preventing taxane‑induced peripheral neuropathy

  2022cites this paper
• Pathophysiology and Therapeutic Perspectives for Chemotherapy-induced Peripheral Neuropathy

  2022cites this paper
• Cellular Pathogenesis of Chemotherapy-Induced Peripheral Neuropathy: Insights From Drosophila and Human-Engineered Skin Models

  2022cites this paper
• Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy

  2022cites this paper
• The growing importance of neuro-oncology for neurologists

  2022cites this paper
• Dynamic Risk Prediction of 30-Day Mortality in Patients With Advanced Lung Cancer: Comparing Five Machine Learning Approaches.

  2022cites this paper
• Genetic Profiles of Ferroptosis in Malignant Brain Tumors and Off-Target Effects of Ferroptosis Induction

  2021cites this paper
• Mitochondrial DNA damage as driver of cellular outcomes.

  2021cites this paper
• Tumortherapieassoziierte neurologische Symptome

  2021cites this paper
• A study concept of expeditious clinical enrollment for genetic modifier studies in CMT1A

  year unknowncites this paper